Skip to main content

Quest Diagnostics Inc(DGX-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low134.63
Day High137.32
Open:135.52
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Firing on All Cylinders Indeed
PR Newswire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
PR Newswire
Neway Forms Lab Services Agreement with Quest Diagnostics to Speed Quality ESRD Testing
PR Newswire
Quest Diagnostics to Release Third Quarter 2023 Financial Results on October 24, 2023
PR Newswire
Quest Diagnostics to Speak at the Baird 2023 Global Healthcare Conference
PR Newswire
Quest Diagnostics Releases 2022 Corporate Responsibility Report
PR Newswire
Quest Diagnostics Granted FDA Breakthrough Designation for its Adeno-associated virus (AAV) Test
ACCESSWIRE
Making Connections To Care: Quest Supports Inspiring Health Equity Event Hosted by Sisters on the Vineyard
Motley Fool
Why Bionano Genomics Stock Tanked Today
PR Newswire
Quest Diagnostics Declares Quarterly Cash Dividend
Motley Fool
More Alzheimer's Treatments Are Coming: This Company Can Help With Early Detection
PR Newswire
Inflammation Marker Signifies Increased Mortality Risk, Finds New Study in PLOS ONE
PR Newswire
Quest Introduces First-To-Market Consumer-Initiated Blood Test for Alzheimer's Disease Risk Assessment on questhealth.com
PR Newswire
Quest Diagnostics Reports Second Quarter 2023 Financial Results; Updates Guidance for Full Year 2023
PR Newswire
Quest Diagnostics Launches Novel Prostate Cancer Test Aimed at Improving Diagnosis and Grading
PR Newswire
Quest Diagnostics Named a 'Best Place to Work for Disability Inclusion' for Sixth Consecutive Year
PR Newswire
Quest Launches Consumer-Initiated Genetic Test on questhealth.com to Deliver Personalized, Actionable Health Risk Insights
GlobeNewswire
Analysis of Half a Billion Lipid Tests from Five Continents Reveals Wide Variation of Heart Disease Lipid Risk by Country and Sex
PR Newswire
Analysis of Half a Billion Lipid Tests from Five Continents Reveals Wide Variation of Lipid-Associated Risk of Heart Disease by Country and Sex
PR Newswire
Quest and Proov Collaborate to Bring Novel Home Fertility Test to Women Through questhealth.com
PR Newswire
Quest Diagnostics to Release Second Quarter 2023 Financial Results on July 26, 2023
PR Newswire
Quest Diagnostics Completes Acquisition of Haystack Oncology, Adding Sensitive MRD Liquid Biopsy Technology to Cancer Diagnostics Portfolio
PR Newswire
Quest Diagnostics to Speak at the Jefferies Global Healthcare Conference
Motley Fool
Want Growing Passive Income? Consider Buying This Stock
PR Newswire
Post-Accident Workforce Drug Positivity for Marijuana Reached 25-Year High in 2022, Quest Diagnostics Drug Testing Index Analysis Finds
PR Newswire
Quest Diagnostics Elects Luis A. Diaz, Jr., M.D. to its Board, Expanding the Number of Directors to 10
PR Newswire
Quest Diagnostics Declares Quarterly Cash Dividend
MarketBeat
Exact Sciences Serves Investors Exactly What They Wished For
PR Newswire
Quest Diagnostics Extends Alzheimer's Disease Portfolio with New AI-Powered Test Service from uMETHOD Health
PR Newswire
Quest Diagnostics Reports First Quarter 2023 Financial Results; Updates Guidance for Full Year 2023
PR Newswire
Quest Diagnostics to Acquire Haystack Oncology, Adding Sensitive Liquid Biopsy Technology for Improving Personalized Cancer Care to Oncology Portfolio
PR Newswire
Quest Diagnostics and NewYork-Presbyterian Complete Laboratory Services Acquisition

Profile

Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services and Diagnostic Solutions. The company's focus is on two elements - to accelerate growth and to drive operational excellence. Restore Growth: The company has adopted seven tactical approaches to accelerate growth such as sales and marketing; development of esoteric testing through a disease focus; partnerships with hospitals and successful testing of international IDNs; creation of value from information assets; leadership in companion diagnostics; extension into adjacent markets. Drive Operational excellence: The company plans to focus on four strategic requirements - to enhance end-to-end customer value chain, enterprise information technology architecture, business performance tools and cost excellence.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2023.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2023 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.